Translational research funding boost
24 November 2017
A prestigious award from the National Health and Medical Research Council (NHMRC) has been presented to Associate Professor Rachael Morton, an Investigator at Melanoma Institute Australia and Research Theme Leader for Society, Policy and Economics.
The NHMRC Translating Research Into Practice (TRIP) Fellowship aims to support future leaders to undertake projects focused on translating evidence into practice that will have a deep impact on health care.
The funding will help researchers at Melanoma Institute Australia continue their ground-breaking research in melanoma that will change the way melanoma treatment is assessed in the future.
A/Prof Morton will use the funding to incorporate Patient Reported Outcome Measures (PROMs) into clinical quality registries.
“PROMs are an important method to better understand outcomes that matter to patients and include any metric assessing health, illness or health care benefits from the patient’s perspective, such as a questionnaire,” explains A/Prof Morton. “In the clinic, PROMs have the potential to highlight relevant symptoms and changes in symptoms, promote patient engagement in their treatment and improve patient outcomes.”
“Instruments measuring the patient’s perspective have been available for decades; however their incorporation into routine clinical practice has until recently been slow. We hope to facilitate this process.”
The work from this Fellowship will help integrate PROMs into the new Australian Clinical Outcomes Register for Melanoma, also known as the Big Data for Melanoma project, which has been made possible by collective fundraising efforts from the national Melanoma March campaign.
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.